CHICAGO–(BUSINESS WIRE)–Level Ex, creators of industry-leading medical video games for physicians, today announced its expansion into cardiology with the launch of Cardio Ex. Their fourth specialty game, available free in the App Store, presents interventional cardiologists with adrenaline-pumping scenarios that push their cognitive, spatial-reasoning, and decision-making skills to the limits—preparing […]
Other News
Tenaya Therapeutics Strengthens Leadership Team with Appointment of Two Biopharmaceutical Industry Veterans
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Tenaya Therapeutics, a biopharmaceutical company focused on developing potentially curative treatments for heart disease, today announced that it has strengthened its leadership team with the appointment of Whittemore Tingley, M.D., Ph.D., as Chief Medical Officer, and Kee-Hong Kim, Ph.D., as Senior Vice President of Manufacturing and […]
Conavi Medical Announces Health Canada Approval of Novasight Hybrid System for Visualization During Coronary Angioplasty Procedures
TORONTO–(BUSINESS WIRE)–Conavi Medical Inc. (www.conavi.com) is pleased to announce that it has received a Health Canada Medical Device License for the Novasight HybridTM System. This patented technology is the only clinical system that enables simultaneous imaging of coronary arteries with both intravascular ultrasound (IVUS) and optical coherence tomography (OCT), and was […]
Itamar Medical Reports Fourth Quarter and Full Year 2018 Financial Results With Record Revenues
CAESAREA, Israel, March 13, 2019 (GLOBE NEWSWIRE) — Itamar Medical Ltd. (Nasdaq & TASE: ITMR), a company that develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea with a focus on the cardiology market, today reported its unaudited financial results for the fourth quarter and full year 2018. […]
Caladrius Biosciences to Host 2018 Fourth Quarter and Year End Financial Results Conference Call on Thursday, March 14, 2019 at 4:30 p.m. Eastern Time
BASKING RIDGE, N.J., March 13, 2019 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company committed to the development of innovative products that have the potential to restore the health of people with chronic illnesses and with a focus on select […]
Esperion Announces Publication of Bempedoic Acid Study 1 Results in The New England Journal of Medicine
ANN ARBOR, Mich., March 13, 2019 (GLOBE NEWSWIRE) — Esperion (NASDAQ:ESPR) announced that results from the 2,230 patient, 52-week, Phase 3 long-term safety study of bempedoic acid (CLEAR Harmony, also known as Study 1 or 1002-040) were published today in The New England Journal of Medicine (NEJM). Bempedoic acid is being […]
Proteon Therapeutics Announces Fourth Quarter and Full-Year 2018 Financial Results
WALTHAM, Mass., March 13, 2019 (GLOBE NEWSWIRE) — Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, today announced its financial results for the year ended December 31, 2018, and recent business highlights. “We are looking forward to […]
Correvio Reports Fourth Quarter and Full Year 2018 Financial Results
Company on Track to Resubmit Brinavess NDA in Q2 2019 Mark H.N. Corrigan, MD to Commence CEO Duties on March 14, 2019 Management to Host Conference Call and Webcast Today, March 13, 2019 at 8:00 a.m. Eastern (5:00 a.m. Pacific) NASDAQ: CORV TSX: CORV VANCOUVER, March 13, 2019 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV / TSX: CORV), a specialty pharmaceutical […]
Neovasc to Announce Year Ended December 31, 2018 Financial Results on Thursday, March 21
Conference Call Scheduled for 4:30pm Eastern Time NASDAQ, TSX: NVCN VANCOUVER, March 13, 2019 /PRNewswire/ – Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today […]
Boston Scientific Receives CE Mark for Next Generation WATCHMAN FLX™ Left Atrial Appendage Closure Device
MARLBOROUGH, Mass., March 13, 2019 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) announced it has received CE Mark and initiated a limited market release of the next generation WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device in Europe. Patients with AF are five times more likely to suffer a stroke than someone with a normal heart […]



